Spago Nanomedical AB (publ) (SPAGO.ST)
SEK 0.23
(1.77%)
SEK 0.23
(1.77%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 52.98 Million SEK | -74.27% |
| 2022 | 205.95 Million SEK | 7.48% |
| 2021 | 191.62 Million SEK | 17.69% |
| 2020 | 162.82 Million SEK | 15.85% |
| 2019 | 140.54 Million SEK | 11.26% |
| 2018 | 126.32 Million SEK | 13.2% |
| 2017 | 111.59 Million SEK | 39.38% |
| 2016 | 80.06 Million SEK | 7.13% |
| 2015 | 74.73 Million SEK | -1.12% |
| 2014 | 75.57 Million SEK | 30.61% |
| 2013 | 57.86 Million SEK | 7.94% |
| 2012 | 53.6 Million SEK | 112.18% |
| 2011 | 25.26 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 57.48 Million SEK | 38.62% |
| 2024 Q1 | 41.46 Million SEK | -21.73% |
| 2023 Q3 | 173.27 Million SEK | -3.18% |
| 2023 FY | 52.98 Million SEK | -74.27% |
| 2023 Q4 | 52.98 Million SEK | -69.42% |
| 2023 Q2 | 178.96 Million SEK | -5.86% |
| 2023 Q1 | 190.11 Million SEK | -7.69% |
| 2022 FY | 205.95 Million SEK | 7.48% |
| 2022 Q3 | 212.59 Million SEK | -7.1% |
| 2022 Q2 | 228.83 Million SEK | 26.68% |
| 2022 Q1 | 180.64 Million SEK | -5.73% |
| 2022 Q4 | 205.95 Million SEK | -3.13% |
| 2021 FY | 191.62 Million SEK | 17.69% |
| 2021 Q2 | 213.28 Million SEK | -3.63% |
| 2021 Q3 | 203.15 Million SEK | -4.75% |
| 2021 Q4 | 191.62 Million SEK | -5.67% |
| 2021 Q1 | 221.32 Million SEK | 35.93% |
| 2020 Q3 | 167.35 Million SEK | -2.55% |
| 2020 Q1 | 136.01 Million SEK | -3.22% |
| 2020 Q4 | 162.82 Million SEK | -2.71% |
| 2020 FY | 162.82 Million SEK | 15.85% |
| 2020 Q2 | 171.73 Million SEK | 26.26% |
| 2019 FY | 140.54 Million SEK | 11.26% |
| 2019 Q1 | 159.16 Million SEK | 26.0% |
| 2019 Q2 | 152.26 Million SEK | -4.33% |
| 2019 Q3 | 149.17 Million SEK | -2.03% |
| 2019 Q4 | 140.54 Million SEK | -5.79% |
| 2018 Q3 | 129.12 Million SEK | 11.31% |
| 2018 FY | 126.32 Million SEK | 13.2% |
| 2018 Q4 | 126.32 Million SEK | -2.17% |
| 2018 Q2 | 116 Million SEK | -0.93% |
| 2018 Q1 | 117.09 Million SEK | 4.93% |
| 2017 Q1 | 78.4 Million SEK | -2.07% |
| 2017 FY | 111.59 Million SEK | 39.38% |
| 2017 Q3 | 74.28 Million SEK | -2.98% |
| 2017 Q4 | 111.59 Million SEK | 50.22% |
| 2017 Q2 | 76.56 Million SEK | -2.35% |
| 2016 Q1 | 71.21 Million SEK | -4.71% |
| 2016 FY | 80.06 Million SEK | 7.13% |
| 2016 Q4 | 80.06 Million SEK | -1.77% |
| 2016 Q3 | 81.51 Million SEK | -2.59% |
| 2016 Q2 | 83.67 Million SEK | 17.5% |
| 2015 Q2 | 71.77 Million SEK | -3.22% |
| 2015 Q1 | 74.15 Million SEK | -1.88% |
| 2015 FY | 74.73 Million SEK | -1.12% |
| 2015 Q4 | 74.73 Million SEK | 6.32% |
| 2015 Q3 | 70.29 Million SEK | -2.06% |
| 2014 Q1 | 60.45 Million SEK | 4.48% |
| 2014 Q4 | 75.57 Million SEK | -2.48% |
| 2014 FY | 75.57 Million SEK | 30.61% |
| 2014 Q2 | 80.32 Million SEK | 32.85% |
| 2014 Q3 | 77.49 Million SEK | -3.51% |
| 2013 Q2 | 48.25 Million SEK | -0.18% |
| 2013 FY | 57.86 Million SEK | 7.94% |
| 2013 Q1 | 48.33 Million SEK | -9.84% |
| 2013 Q3 | 47.94 Million SEK | -0.63% |
| 2013 Q4 | 57.86 Million SEK | 20.69% |
| 2012 FY | 53.6 Million SEK | 112.18% |
| 2012 Q3 | 29.38 Million SEK | 0.0% |
| 2012 Q4 | 53.6 Million SEK | 82.44% |
| 2011 FY | 25.26 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Abliva AB (publ) | 87.49 Million SEK | 39.445% |
| Aptahem AB (publ) | 63.02 Million SEK | 15.93% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 55.268% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 96.216% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 97.212% |
| Cantargia AB (publ) | 223.71 Million SEK | 76.316% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -256.345% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 93.03% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -75.604% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 32.668% |
| Fluicell AB (publ) | 9.34 Million SEK | -467.291% |
| Genovis AB (publ.) | 288.85 Million SEK | 81.657% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 94.795% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 84.919% |
| Mendus AB (publ) | 755.95 Million SEK | 92.991% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 70.085% |
| Kancera AB (publ) | 65.64 Million SEK | 19.283% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 95.789% |
| Lipum AB (publ) | 12.11 Million SEK | -337.531% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -57.684% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 80.992% |
| Nanologica AB (publ) | 77.42 Million SEK | 31.57% |
| Saniona AB (publ) | 64.14 Million SEK | 17.396% |
| Simris Alg AB (publ) | 174.55 Million SEK | 69.645% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 89.323% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 91.892% |
| Xintela AB (publ) | 18.39 Million SEK | -188.04% |
| Ziccum AB (publ) | 14.97 Million SEK | -253.894% |
| Active Biotech AB (publ) | 44 Million SEK | -20.42% |
| CombiGene AB (publ) | 120.61 Million SEK | 56.07% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -26.278% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | 15.057% |
| LIDDS AB (publ) | 17.65 Million SEK | -200.113% |
| Biovica International AB (publ) | 131.4 Million SEK | 59.679% |
| NextCell Pharma AB | 81.28 Million SEK | 34.818% |
| Amniotics AB (publ) | 26.08 Million SEK | -103.117% |
| BioArctic AB (publ) | 1.18 Billion SEK | 95.533% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | 14.749% |
| Corline Biomedical AB | 100.1 Million SEK | 47.071% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 75.587% |
| Intervacc AB (publ) | 259.61 Million SEK | 79.591% |
| AcouSort AB (publ) | 34.51 Million SEK | -53.522% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -164.383% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 93.076% |
| SynAct Pharma AB | 228.01 Million SEK | 76.763% |
| OncoZenge AB (publ) | 20.34 Million SEK | -160.497% |
| Camurus AB (publ) | 1.9 Billion SEK | 97.223% |
| 2cureX AB (publ) | 16.62 Million SEK | -218.707% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -771.894% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 62.314% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -144.138% |
| I-Tech AB | 152.44 Million SEK | 65.243% |
| Cyxone AB (publ) | 43.65 Million SEK | -21.372% |
| Biosergen AB | 7.2 Million SEK | -635.801% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -97.979% |
| Alzinova AB (publ) | 123.18 Million SEK | 56.989% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 77.773% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 37.831% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -526.671% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 39.148% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -85.86% |